Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: The guidelines proposed by Dr Brennan and colleagues1 to mitigate the influence of pharmaceutical company marketing strategies on physician prescribing habits in the United States provide a long overdue template to inform policy formulation by drug regulatory bodies elsewhere in the developed world. However, in concentrating on the relationship between pharmaceutical companies and AMCs, these guidelines divert attention from general practitioner vulnerability to being influenced by pharmaceutical company incentives.
Ting JYS. Academic Medical Centers and Conflicts of Interest. JAMA. 2006;295(24):2845-2849. doi:10.1001/jama.295.24.2846-a